Today, #Kognitic released our #Covid_19 dashboard which leverages #machinelearning to capture data from Covid-19 #clinicaltrials in real-time. This portal integrates industry data to provide high-level insights regarding the modality of covid-19 interventions, industry developments, and trial completion timelines. Kognitic hopes in sharing data captured directly from the clinical trials, to reduce the ambiguity of coronavirus news by empowering all to interrogate the data and

Merck KGaA's MET inhibitor, Tepotinib, received approval in Japan for #NSCLC yesterday, gaining a lead in the tight race against Capmatinib - Novartis' MET inhibitor. The two continue to strive for approval in the United States. #Kognitic's platform highlights the timeline for ongoing trials for both these drugs below. The approval for Tepotinib comes from Merck KGaA's ongoing Vision trial. #Oncology #Analytics #AI #Cancer #LungCancer #Data #Automated #Pharma #MachineLearning

#Roche presented its late stage pipeline today at #JPM20, with #tecentriq heading up #oncology with six anticipated indications, including expansions in #HCC, #TNBC, #bladdercancer, #melanoma, #ovariancancer, and #NSCLC. In what other indications and patient segments is tecentriq being tested? #Kognitic's platform makes this information accessible in real-time for clients curious about what is next for this momentum-building asset! See image below for #insights into tecentriq

A next generation CD-19 mAb, tafasitamab is all the buzz at #JPM2020! #Incyte acquired tafasitamab from #Morphosys, who had been developing the drug under the code name MOR00208 (see link below). While the pipeline for targeting CD-19 has been overwhelmingly CAR-T, tafasitamab is leading the way for increased investment in CD-19 antibodies! #Kognitic's platform enhances big pharma portfolio strategies by giving access to real-time data of all target landscapes. View the ima

#JPM2020 is right around the corner! The #Kognitic team is excited to hear from numerous industry leaders what is next for the pharma industry, including keynote speaker Emma Walmsley, CEO at #GlaxoSmithKline! As GSK is currently developing assets across almost 50 cancer indications, she will undoubtedly have great insights to share. See Kognitic's bullseye view below for more detail about GSK's oncology assets! #Oncology #Cancer #AI #Insights #StartupHealth #GSK #Pipeline